A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 2, 2006, Pages 153-157

  Pacifico, A ^a   Daidone, R ^a   Peris, Ketty ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Corticosteroid; Occlusion; Plaque psoriasis; Topical therapy

Indexed keywords

BETAMETHASONE VALERATE; HYDROCORTISONE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYDRATION; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN DEFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND DRESSING; CHEMISTRY; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROTECTIVE CLOTHING; QUESTIONNAIRE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BETAMETHASONE 17-VALERATE; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OCCLUSIVE DRESSINGS; PROSPECTIVE STUDIES; PSORIASIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646266259     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01387.x     Document Type: Article

References (23)

1. Naldi L, Colombo P, Placchesi EB et al. Study design and preliminary results from the pilot phase of the PraKtis study: Self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004; 208: 38-42.
2. Feldman SR, Fleisher AB Jr, Reboussin DM et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-569.
3. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002; 45: 255-261.
4. Finzi AF, Mantovani LG, Bellisari A. The cost of hospital-related care of patients with psoriasis in Italy based in the AISP study. J Eur Acad Dermatol Venereol 2001; 15: 320-324.
5. Linden KG, Weinstein GD. Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 1999; 107: 595-605.
6. Lebwohl M, Suad A. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-498.
7. Van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003; 16: 69-83.
8. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121: 63-67.
9. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Clinical pharmacology and therapeutic use. Am J Dermatol 2002; 3: 47-58.
10. Giannotti B, Pimpinelli N. Topical corticosteroids. Which drug and when? Drugs 1992; 44: 65-71.
11. Van der Vleuten CJM, Van Vlijmen-Willems IMJJ, De Jong EMJC, Van de Kerkhof PCM. Clobetasol-17-propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: An immunohistochemical study on remission and relapse. Arch Dermatol Res 1999; 291: 390-395.
12. Van Vlijmen-Willems IMJJ, Chang A, Boezeman JBM, Van de Kerkhof PCM. The immunohistochemical effect of a hydrocolloid occlusive dressing (DuoDERM E) in psoriasis vulgaris. Dermatology 1993; 187: 257-262.
13. Feldman SR, Fleischer AB, Reboussin DM et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996; 106: 183-186.
14. Katz HI, Prawer SE, Medansky RS et al. Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse-dose treatment regimen. Dermatologica 1991; 183: 269-274.
15. Faber WR, Van Joost Th, de Hoop D et al. Effectiveness usability of short-time treatment of psoriasis vulgaris with two different corticosteroids under occlusion with a hydrocolloid dressing (Contreet). J Eur Acad Dermatol Venereol 1995; 5: 157-162.
16. Volden G, Kragballe K, van de Kerkhof PCM, Aberg K, White RJ. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol proprionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat 2001; 12: 141-144.
17. Baxter DL, Stoughton RB. Mitotic index of psoriatic lesions treated with anthralin, glucocorticosteroid and occlusion only. J Invest Dermatol 1970; 54: 410-412.
18. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986; 115: 475-484.
19. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. Drugs 1998; 36: 51-61.
20. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303-307.
21. Franz TJ, Parsell DA, Haluani RM et al. Bethametasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-632.
22. Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician 1990; 41: 1531-1538.
23. Fisher DA. Adverse effects of topical corticosteroids use. West J Med 1995; 162: 123-126.